Stocks
Allogene Therapeutics (ALLO) EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -169.7 | -321.2 | -313.1 | -243.3 | -177.5 | -168.1 | ||
| Changes by years, y/y, % | -29% | +89% | -3% | -22% | -27% | -5.8% | |||
Allogene Therapeutics. EBITDA US GAAP, bln rub
Allogene Therapeutics. EBITDA US GAAP, changes, %
Allogene Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Allogene Therapeutics (ALLO) EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | -56.5 | -47.6 | -38.0 | -35.4 | -39.4 | -168.1 | |
| Changes by years, y/y, % | -8% | -24% | -40% | -37% | -30% | |||
| Changes by quarters, q/q, % | +1% | -16% | -20% | -7% | +11% | |||
